However, despite the fact that over the last 20 years great progress has been made in the field of PSMA-targeted radionuclide prostate cancer therapy, there is still only a small number of clinical trials including approximately 400 mCRCP patients treated with antibody-based molecules conjugated to β− emitters. This evidence concerns the gene FOLH1 and prostate cancer.